$9.080
-0.252 (-2.78%)終値時点
MSLE のニュース
MSLE のイベント
Satellos Files $300M Mixed Securities Shelf
Satellos files $300M mixed securities shelf
Satellos Receives FDA Fast Track Designation for SAT-3247
Satellos announced that the FDA has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. The company is currently advancing SAT-3247 through its ongoing Phase 2 BASECAMP and TRAILHEAD studies in children and adults living with Duchenne.
Satellos Raises $57M to Advance Clinical Trials
"The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted to Nasdaq, and advanced the Phase 2 TRAILHEAD and BASECAMP studies," said Frank Gleeson, CEO of Satellos. "We are excited by the progress we are making with BASECAMP enrollment and dosing across 11 active clinical sites to date. We expect the additional sites intended to complete BASECAMP to be activated in Q2. We remain on track to complete BASECAMP enrollment in Q3 2026, supported by the active and planned sites currently having identified more than 100% of potential participants for screening and potential enrollment in the coming months."
Satellos Bioscience Stock Trading Halted
Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause
Satellos Bioscience Releases Interim Clinical Data for SAT-3247
Satellos Bioscience announced interim clinical and biomarker data for SAT-3247 at the Muscular Dystrophy Association, MDA, Clinical & Scientific Conference in Orlando, Florida. The data include interim observations from the ongoing Phase 2 TRAILHEAD study in adults with DMD serum proteomic analysis from the previously completed 28-day, CL-101 Phase 1a/b trial, and the development of a novel muscle regeneration assessment tool. The Company also presented preclinical findings demonstrating enhanced muscle strength in a mouse model of FSHD. Interim observations from the ongoing Phase 2 TRAILHEAD study include: Continued increase in handgrip strength compared to CL-101 baseline; Overall stability in elbow and shoulder strength at Day 56 following re-enrollment; Greater improvement in strength observed among participants with greater baseline muscle mass; Additional clinical outcome assessments ongoing
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。